Since the surveys were implemented, many more countries have initiated transition to dolutegravir-containing regimens, providing people with a better treatment option and strengthening the fight against drug resistance.
Pre-exposure prophylaxis (PrEP) is an effective prevention option for HIV-negative individuals at substantial risk of HIV infection as part of combination prevention approaches.
12954
如果在未确诊的急性艾滋病毒感染环境下开始暴露前预防，则最有可能发生耐药性。
Resistance is most likely to occur when PrEP is started in the setting of undiagnosed acute HIV infection.
As countries implement PrEP to prevent HIV infection, it should be accompanied by surveillance of HIV drug resistance in people who become infected despite use of PrEP.
12956
报告指出，实现高水平病毒抑制的国家数量（≥90%）从2017年的33%增加到2020年的80%。
The report indicates that the number of countries achieving high levels of viral suppression (≥90%) increased from 33% in 2017 to 80% in 2020.
Achieving high levels of viral load suppression in populations taking antiretroviral therapy prevents transmission of HIV, HIV-associated morbidity and mortality and prevents emergence of HIV drug resistance.
The report also emphasizes the need for routine viral load monitoring and close follow-up of individuals with viral non-suppression, including regimen switch if indicated, to achieve favourable and sustained long term treatment outcomes.
12959
此外，确保用于治疗艾滋病毒感染的最佳药品的持续可用性和可及性对于预防艾滋病毒耐药性至关重要。
In addition, ensuring the continuous availability and accessibility to optimal medicines to treat HIV infections is essential to prevent HIV drug resistance.
These findings emphasize the need to support countries in proactively finding sustainable solutions that are appropriate to local contexts and can involve community members and civil society.